Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Extension Study of Adjuvanted RSVPreF3 Vaccine in Lung and Kidney Transplant Recipients
jRCT2071250049Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (2 arms), sponsored by GSK. Primary endpoints: RSV-A neutralizing antibody GMTs, RSV-B neutralizing antibody GMTs and 2 more. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2071250049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250049.